MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: Achieving activity in vivo through the use of alternative scaffolds

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 23, 2003, Pages 4205-4208

  Nakayama, Kiyoshi ^a   Ishida, Yohei ^a   Ohtsuka, Masami ^a   Kawato, Haruko ^a   Yoshida, Ken Ichi ^a   Yokomizo, Yoshihiro ^a   Ohta, Toshiharu ^a   Hoshino, Kazuki ^a   Otani, Tsuyoshi ^a   Kurosaka, Yuichi ^a   Yoshida, Kumi ^a   Ishida, Hiroko ^a   Lee, Ving J ^b   Renau, Thomas E ^b   Watkins, William J ^b  

^a DAIICHI SANKYO CO   (Japan)

^b Essential Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LEVOFLOXACIN; MEMBRANE EFFLUX AB OPRM PROTEIN INHIBITOR; PIPERAZINE; PLASMA PROTEIN; PROTEIN INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; ROSOXACIN; SITAFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; GRAM NEGATIVE INFECTION; IN VIVO STUDY; MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; PSEUDOMONAS AERUGINOSA;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 10744222660     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.07.027     Document Type: Article

References (21)

1. Chanda S.K., Caldwell J.S. Drug Discov. Today. 8:2003;168.
2. Lipinski C.A. J. Pharmacol. Toxicol. Methods. 44:2000;235.
3. Nakayma, K.; Ishida, Y.; Ohtsuka, M.; Kawato, H.; Yoshida, K.; Yokomizo, Y.; Hosono, S.; Ohta, T.; Hoshino, K.; Ishida, H.; Yoshida, K.; Renau, T. E.; Léger, R.; Zhang, J. Z.; Lee, V. J.; Watkins, W. J. Bioorg. Med. Chem. Lett. See preceding paper in this issue doi: 10.1016/j.bmcl.2003.07.024.
4. Poole K., Krebes K., McNally C., Neshat S. J. Bacteriol. 175:1993;7363.
5. Poole K., Gotoh N., Tsujimoto H., Zhao Q., Wada A., Yamasaki T., Neshat S., Yamagishi J., Li X.Z. Nishino Mol. Microbiol. 21:1996;713.
6. Koehler T., Michea-Hamzehpour M., Henze U., Gotoh N., Curty L.K., Pechere J.C. Mol. Microbiol. 23:1997;345.
7. Mine T., Morita Y., Kataoka A., Mizushima T., Tsuchiya T. Antimicrob. Agents Chemother. 43:1999;415.
8. Belanger P.C., Dufresne C. Can. J. Chem. 64:1986;1514.
9. Hirschmann R., Nicolaou K.C., Pietranico S., Salvino J., Leahy E.M., Sprengeler P.A., Furst G., Smith A.B. III, Strader C.D., Cascieri M.A., Candelore M.R., Donaldson C., Vale W., Maechler L. J. Am. Chem. Soc. 114:1992;9217.
10. Hirschmann R., Nicolaou K.C., Pietranico S., Leahy E.M., Salvino J., Arison B., Cichy M.A., Spoors P.G., Shakespeare W.C., Sprengeler P.A., Hamley P., Smith A.B. III, Reisine T., Raynor K., Maechler L., Donaldson C., Vale W., Freidinger R.M., Cascieri M.A., Strader C.D. J. Am. Chem. Soc. 115:1993;12550.
11. Hirschmann R., Hynes J. Jr., Cichy M.A., van Rijn R.D., Sprengeler P.A., Spoors P.G., Shakespeare W.C., Pietranico S., Barbosa J., Liu J., Yao W., Rohrer S., Smith A.B. III J. Med. Chem. 41:1998;1382.
12. Olson G.L., Cheung H.-C., Chiang E., Madison V.S., Sepinwall J., Vincent G.P., Winokur A., Gary K.A. J. Med. Chem. 38:1995;2866.
13. Nakayama K., Kawato H.C., Inagaki H., Ohta T. Org. Lett. 3:2001;3447.
14. Zlotos G., Bucker B., Kinzig-Schippers M., Sorgel F., Holzgrabe U. J. Pharma. Sci. 87:1998;215.
15. Catalyst™, version 4.6, Accelrys, Inc., San Diego, CA, 2002.
16. Carini D.J., Duncia J.V., Pierce M.E. Pharm. Biotechnol. 11:1998;29.
17. Mozek I., Sket B. J. Heterocycl. Chem. 31:1994;1293.
18. Kanno H., Yamaguchi H., Ichikawa Y., Isoda S. Chem. Pharm. Bull. 39:1991;1099.
19. Lomovskaya O., Lee A., Hoshino K., Ishida H., Mistry A., Warren M.S., Boyer E., Chamberland S., Lee V. J. Antimicrob. Agents Chemother. 43:1999;1340.
20. Lomovskaya O., Warren M.S., Lee A., Galazzo J., Fronko R., Lee M., Blais J., Cho D., Chamberland S., Renau T., Léger R., Hecker S., Watkins W., Hoshino K., Ishida H., Lee V. Antimicrob. Agents Chemother. 45:2001;105.
21. 6 CFU/mouse). All drugs were administered as a bolus, iv, via the tail vein. LVFX and STFX were dosed as a solution in 0.1 N NaOH immediately after inoculation, followed (in potentiation experiments) by the EPI. 6 was formulated in EtOH/Cremaphore EL/phosphate buffer (pH 7) (5:5:45:45); 8 was formulated in EtOH/Cremaphore EL/0.1 N NaOH/phosphate buffer (pH 7) (5:5:45:45) or EtOH/PEG400/0.1 M NaOH (5:5:90).